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Sera were collected from 185 adults aged ≥ 70 years in 
London to evaluate the immune response to COVID-
19 vaccines. A single dose of Pfizer/BioNtech vaccine 
resulted in > 94% seropositivity after 3 weeks in naïve 
individuals using the Roche Spike antibody assay, 
while two doses produced very high spike antibody 
levels, significantly higher than convalescent sera 
from mild-to-moderate PCR-confirmed adult cases. 
Our findings support the United Kingdom’s approach 
of prioritising the first dose and delaying the second 
dose of COVID-19 vaccine.
In the United Kingdom (UK), the Joint Committee on 
Vaccination and Immunisation (JCVI) recommended 
extending the interval between coronavirus disease 
(COVID-19) vaccine doses from the authorised 3–4 
weeks up to 12 weeks in order to maximise the roll-
out of the first dose of vaccine to those at highest 
risk of death due to COVID-19 [1]. The COVID-19 vac-
cine responses after  extended immunisation  sched-
ules (CONSENUS) evaluation aimed to assess immune 
responses to the extended immunisation schedule 
which was implemented across the UK from 8 December 
2020. In this report, we present severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) antibody 
responses in the first 185 adults aged 70–90 years, 
recruited from the end of January 2021 through North 
London primary care networks, who were tested ca 3 
weeks either after their first or second Pfizer/BioNTech 
(Mainz, Germany) vaccine dose received as part of 
the national programme. Responses were compared 
with 100 convalescent samples collected from clini-
cally mild-to-moderate PCR-confirmed adult COVID-19 
cases, ca 3–6 weeks after onset of symptoms.
Serological testing
Serum samples were tested with five different anti-
body assays: two for antibodies against the nucleo-
protein (N) (SARS-CoV-2 IgG assay, Abbott, Illinois, 
United States and Elecsys Anti-SARS-CoV-2 total anti-
body assay, Roche Diagnostics, Basel, Switzerland 
[2,3]) to identify prior SARS-CoV-2 infection, and three 
for antibodies against the spike (S) protein to assess 
vaccine response (Roche immunoassay, Elecsys Anti-
SARS-CoV-2 S total antibody assay, Roche Diagnostics; 
an in-house receptor binding domain (RBD) indirect 
IgG ELISA [4]; and a lateral flow total antibody device 
(LFD), Fortress Diagnostics, Antrim, UK); the latter is 
currently used in the national Real-time Assessment of 
Community Transmission (REACT) study in the UK [5]. 
For the Abbott assay, results were expressed as a cut-
off index (positive ≥ 1.4). Roche anti-N IgG results were 
expressed as a cut-off index (positive ≥ 1.0), and anti-
S IgG as arbitrary units (au)/mL (positive ≥ 0.8 au/mL). 
For the RBD assay, results were expressed as an index 
calculated as the ratio test:negative (positive ≥ 5.0). 
For the LFD, 10 μL of serum were directly applied to 
the cartridge in the testing laboratory using the blood 
sample obtained through venepuncture. The devices 
were read by three independent observers and a con-
sensus result derived. Only the IgG result was scored. 
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Figure 1
SARS-CoV-2 antibody levels in RBD and Roche S assays by age group, N antibody status and vaccine dose, London, United 
Kingdom, January–February 2021 (n = 185)
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A.  SARS-CoV-2 antibody detected by RBD assay after one dose of 
       Pfizer/BioNTech vaccine (n = 99)
B. SARS-Cov-2 antibody detected by RBD assay after two 
     doses of Pfizer/BioNTech vaccine (n = 86)
C. SARS-CoV-2 antibody detected by Roche S assay after one dose 
      of Pfizer/BioNTech vaccine (n = 99)
D. SARS-Cov-2 antibody detected by Roche S assay after 
      two doses of Pfizer/BioNTech vaccine (n = 86)
N+: nucleoprotein-positive; N−: nucleoprotein-negative; RBD: receptor-binding domain assay; S: spike protein assay; SARS-CoV-2: severe 
acute respiratory syndrome coronavirus 2.
The horizontal line indicates the cut-off between positive and negative for each of the assays.
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All commercial assays were performed according to the 
manufacturer’s instructions.
 
Vaccine responses
 
Seropositivity with the Roche anti-N-antibody assays 
was interpreted as evidence of previous infection, 
while lack of antibody to nucleoprotein and presence 
of spike protein antibody indicated vaccine response.
Fifteen of the 185 individuals (8%) were nucleoprotein 
antibody-positive using the Roche anti-N assay, includ-
ing 10 who were also positive using the Abbott assay. 
Previous studies have shown that the sensitivity of 
the Abbott assay declines more rapidly compared with 
the Roche assay, indicating that those who were nega-
tive in the Abbott assay had been infected more than 
3 months previously [6]. The nucleoprotein antibody 
seropositivity of 8% in our cohort is similar to commu-
nity seroprevalence of 11% among ≥ 70-year-old blood 
donors between 18 January and 14 February 2021 in 
London [7].
In this cohort, 99 individuals were enrolled after 
receiving one dose of Pfizer/BioNTech vaccine and 86 
individuals were enrolled after receiving two doses 3 
weeks apart. All individuals had a blood test ca 3 weeks 
after vaccination. In those who had received their first 
dose of vaccine (n = 99), sera were collected at day 0 
and days 18–33 and in those who received two doses 
(n = 86), sera were only collected between days 21 and 
25 after their second dose. All 86 individuals were spike 
protein antibody-positive in all three assays. After two 
vaccine doses, antibody titres were significantly higher 
in those with prior SARS-CoV-2 infection (nucleopro-
tein antibody-positive) compared with previously unin-
fected individuals (twofold by RBD; 20-fold by Roche S 
for those aged 70–79 years, Figure 1 and Table 1). There 
was no evidence of a boosting response to the second 
dose of vaccine in those who were previously infected 
with SARS-CoV-2.
Of the 92 individuals tested 3 weeks after their first 
dose of Pfizer/BioNTech vaccine and with no evidence 
of previous SARS-CoV-2 infection, 71 (77%) were posi-
tive in the RBD assay, 71 (77%) by LFD and 87 (95%) 
in the Roche anti-S assay. Antibody levels were slightly 
lower among ≥ 80-year-olds than 70–79-year-olds in 
both quantitative assays but the difference was not 
statistically significant (Table 1).
Comparing responses to vaccine and 
natural infection
Geometric mean antibody concentrations in those 
with and without prior infection were compared with 
100 convalescent sera taken 3–6 weeks after PCR-
confirmed infection among 15–98-year-olds (mean age: 
50 years). Antibody levels after one vaccine dose in 
previously uninfected individuals were lower than con-
valescent sera using the RBD assay but similar when 
using the Roche anti-S assay (Figure 2 and Table 2).
After two vaccine doses, antibody concentrations in 
previously uninfected individuals were significantly 
higher in the vaccinated group than convalescent sera 
Table 1
RBD assay and Roche S measurements and Fortress lateral flow outcomes by age group, 3 weeks after first or second dose 
Pfizer/BioNTech vaccine, London, United Kingdom, January–February 2021 (n = 185)
Pfizer/BioNTech 
dose
Age group 
 
(years)
Total
RBD Roche S Lateral flow
Number of 
positives
Geometric 
mean antibody 
concentrations (95% 
CI)
Number of 
positives
Geometric 
mean antibody 
concentrations 
 
(95% CI)
Number of 
positives
Roche N-negative
1 70–79 49 42 11.9 (9.3–15.2) 47 27.1 (18.2–40.4) 40
1 80–89 43 29 10.1 (7.4–13.9) 40 19.6 (11.5–33.5) 31
2 70–79 50 50 45.2 (40.5–50.3) 49 740.4 (564.1–971.8) 50
2 80–89 28 28 39.7 (31.7–49.8) 28 640.3 (373.3–1,098.1) 28
Roche N-positive
1 70–79 2 2 98.1 (61.8–155.9) 2 23,338 (746.8–729,398) 2
1 80–89 5 5 80.8 (46.5–140.2) 5 5,034.4 (252.4–100,431) 5
2 70–79 7 7 76.2 (63.9–90.8) 7 17,998 (4,378.7–73,982) 7
2 80–89 1 1 41.3 1 150 1
Convalescent sera
Not applicable 15–98 100 91 29 (23.1–36.4) 93 31 (20.3–47.3) Not done
CI: confidence interval; N: nucleoprotein; RBD: receptor-binding domain assay; S: spike protein assay.
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using either S-antibody assay, with > 10-fold higher con-
centrations in the Roche anti-S assay. In previously 
infected individuals, a single vaccine dose produced 
significantly higher antibody levels than convalescent 
sera. Two vaccine doses, however, did not significantly 
increase the geometric mean ratio (Table 2).
Discussion
Unlike North American and many European countries 
that vaccinated according to the licensed schedule, 
the JCVI in the UK recommended prioritising the first 
dose of vaccine and delaying the second dose for up 
to 12 weeks. This decision was made at a time when 
there was a rapid increase in COVID-19 cases, hospi-
talisations and deaths in the UK [3] and a single dose 
of Pfizer/BioNtech COVID-19 vaccine was estimated to 
provide 90% protection against COVID-19 after 2 weeks 
[2]. The policy was supported by modelling suggesting 
vaccinating a greater number of people with a single 
dose would prevent more deaths and hospitalisations 
than vaccinating fewer people with two doses [4].
Our findings demonstrate that adults aged ≥ 70 years 
mount robust antibody responses 3 weeks after a sin-
gle dose of the Pfizer/BioNtech vaccine, with more than 
94% previously uninfected individuals seroconverting 
after 3 weeks using the Roche S assay. These results 
are particularly important given the limited data that 
are available for older adults in prelicensure COVID-19 
vaccine trials.
Antibody responses after a single vaccine dose were 
significantly higher in previously infected vaccinees, 
consistent with similar reports in younger healthcare 
workers [8]. Two doses of vaccine produced very high 
spike antibody levels, with significantly higher anti-
body levels in those with prior SARS-CoV-2 infection. 
In previously infected individuals, however, there was 
no evidence of boosting to the second vaccine dose 
when administered 3 weeks following the first dose. 
This finding supports the approach adopted in some 
countries, such as France recommending a 3-week 
schedule, to offer only one dose of vaccine to those 
with previously confirmed SARS-CoV-2 infection [9]. 
Figure 2
Reverse cumulative distribution plot of log (base 10) RBD or Roche S assay measurements in N-negative CONSENSUS 
participants by vaccine and convalescent sera, indicating relative antibody levels, London, United Kingdom, January–
February 2021 (n = 285)
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When compared with convalescent sera from clinically 
mild-to-moderate PCR-confirmed cases in adults, anti-
body levels were significantly higher after two doses of 
vaccine in those aged ≥ 70 years and also after a single 
dose of vaccine in previously infected individuals.
Conclusion
Our findings provide additional support for the UK 
approach of prioritising the first dose of vaccine and 
is consistent with recent real-world data demonstrat-
ing high protection after one dose against SARS-
CoV-2 infection, COVID-19, hospitalisation and deaths 
in the older population in the UK [10] and Israel [11]. 
The data are also in keeping with community sero-
prevalence data in blood donors showing a rapid rise 
in prevalence of spike protein antibody-positive but 
nucleoprotein-antibody negative adults [12]. Antibody 
responses in our cohort were significantly higher com-
pared with recent estimates using self-collected LFDs 
in the vaccinated people in the community, even when 
compared with LFD results in this analysis, suggest-
ing that this collection method may not be suitable for 
assessing vaccine responses through home testing for 
older adults [13]. Further studies are ongoing to assess 
antibody and cellular responses as well as antibody 
waning in adults and older adults receiving extended-
interval schedules with any COVID-19 vaccine.
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